

1 **Atrial Fibrillation Inpatient Management Patterns and Clinical Outcomes**
2 **During The Conflict In Syria: An Observational Cohort Study**

3 Ibrahim Antoun^{1,2}, Alkassem Alkhayer³, Ahmed Kotb¹, Ibrahim Hanafi⁴, Yaman
4 Mahfoud³, Joseph Barker⁶, Akash Mavilakandy¹, Alamer Alkhayer³, Saif Shah⁸,
5 Peter Simon³, Riyaz Somani^{1,7}, G Andre´ Ng^{1,5,7}

6 1. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

7 2. Faculty of Medicine, University of Aleppo, Aleppo, Syria

8 3. University of Tishreen’s Hospital, Latakia, Syria

9 4. University of Damascus, Damascus, Syria

10 5. NIHR Leicester Biomedical Research Centre

11 6. National Heart and Lung Institute, Imperial College London, London, UK

12 7. Department of Cardiology, University Hospitals of Leicester NHS Trust, Glenfield
13 Hospital, Leicester, UK

14 8. Department of General Acute Medicine, University Hospitals of Leicester,
15 Leicester, UK

16

17 Corresponding author

18 Ibrahim Antoun MD MRCP PhD

19 Department of Cardiovascular Sciences

20 Glenfield Hospital | Groby Road | Leicester | LE3 9QP | UK

21 +44 (0)116 250 2366

22 ibrahim.antoun1@nhs.net

23

24 Keywords: Syria, atrial fibrillation, Rhythm control

25

26 **Abstract**

27 **Background**

28 Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide. However, there is no data
29 on AF inpatient management strategies and clinical outcomes in Syria.

30 **Objectives**

31 This study aims to navigate AF inpatient management and cardiovascular (CV) mortality in a tertiary
32 cardiology centre in Latakia, Syria.

33 **Methods**

34 A single-centre retrospective observational cohort study was conducted at Tishreen's University
35 Hospital, Latakia, Syria, from June 2021 to June 2023. We included patients ≥ 16 years of age
36 presenting and being treated for AF as the primary diagnosis at the emergency department. Medical
37 records were examined for patient demographics, laboratory results, treatment plans and inpatient
38 details. Inpatient cardiovascular mortality was the primary outcome of interest.

39 **Results**

40 The study included 596 patients. The median age was 58 and 61% were males. Only 121 patients
41 (20.3%) were known to have AF. Rhythm control strategy was persuaded in 39% of patients, with
42 Amiodarone being the only agent utilised while the rest adopted a rate control approach. CV Mortality
43 occurred in 28 patients (4.7%). The presence of smoking (aOR: 1.6, 95% CI: 1.3 to 2.1, $P=0.04$),
44 thyroid disease (aOR= 9.7, 95% CI= 1.2 to 91.6, $P<0.001$), COPD (aOR: 82, 95% CI: 12.7 to 711,
45 $P<0.001$) and valvular heart disease (VHD) (aOR= 9.1, 95% CI: 1.7 to 55.1, $P<0.001$) were
46 independent risk factors of cardiovascular inpatient mortality.

47 **Conclusion**

48 Current smoking, thyroid disease, COPD and VHD were independent risk factors of inpatient
49 cardiovascular mortality with AF in Syria. Elective rhythm control was challenging due to limited
50 resources.

51

52 **Background**

53 Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, and
54 prevalence in low to middle-income countries is likely underestimated (1). Although
55 AF in the Western world is extensively studied, little data corroborates AF
56 demographics and management in the Middle East, with only four epidemiological
57 data registries (2). AF-related research is still insufficient in the Arab world,
58 contributing only 0.7% of the total AF research (3).

59 One of these countries, Syria, has been in conflict since 2011 and deprived of
60 healthcare resources and funding, particularly exacerbated during the COVID-19
61 pandemic. As a result, less than half of its hospitals operate at full performance, with
62 over 50% of its healthcare workforce forced to leave due to conflict. More than half
63 the Syrian population live in poverty, which is suggested to increase AF risk (4). The
64 AF management in hospitals during the accompanying political and economic turmoil
65 is unclear, with a lack of published inpatient outcomes and figures originating from
66 Syrian hospitals. In the context of the constraint resources, a real-world depiction of
67 currently practised AF care and observed outcomes could potentially aid
68 management and allocation of resources by identifying remediable areas of
69 deficiencies and, more importantly, reasonable and practical solutions that could be
70 implemented.

71 We aimed to describe the characteristics and outcomes of patients treated for AF in
72 Latakia's cardiology tertiary care centre over two years.

73

74

75

76 **Methods**

77 This is a single-centre retrospective observational cohort study conducted at
78 Tishreen's University Hospital, Latakia, Syria, between the 1st of June 2021 and the
79 1st of June 2023. Ethical approval was obtained by the hospital board and the ethical
80 board at Tishreen's University Hospital (reference: 277/A).

81 Inclusion criteria were adult patients (over the age of 16 years) presenting to the
82 hospital and treated for AF as the primary diagnosis. Patients exhibiting AF as a
83 secondary component or complication to another primary diagnosis were excluded.
84 The diagnosis of AF was established by 12-lead electrocardiograms (ECG) and
85 subsequently interpreted and verified by a consultant cardiologist.

86 Patient demographics, admission details, 12-lead ECGs, blood results, radiological
87 reports and clinical outcomes during hospitalisation were extracted from patients'
88 records. The primary outcomes included the length of hospital stay and in-hospital
89 cardiovascular (CV) mortality. The study was written according to STROBE
90 guidelines — see Supplementary Table 1 (5).

91

92 **Statistical analysis**

93 Continuous variables are expressed as median and interquartile ranges (IQR).
94 Categorical variables are expressed as counts and percentages (%).
95 Pearson's χ^2 or Fisher's exact test was used for categorical variables between
96 groups. Student's *t*-test and Kruskal-Wallis test were used to compare continuous
97 variables between the groups depending on the normality of the distribution.

98 Multiple logistic regression models were used to investigate the relationship between
99 variables and mortality. We hypothesised that specific demographic characteristics
100 and comorbidities would affect AF mortality. Therefore, we constructed a base model
101 consisting of age and gender to assess the incremental value of comorbidities that
102 are significantly associated with mortality. These comorbidities were then added to
103 the base model to improve the mortality predictability of the model. The new model's
104 cumulative discrimination was measured using the area under the curve; its
105 statistical significance compared to the base model was assessed with the likelihood
106 ratio test. A 2-sided p-value <0.05 was considered statistically significant. Statistical
107 analysis was performed using GraphPad Prism V10.0 for Mac (San Diego,
108 California, USA; www.graphpad.com).

109

110 **Results**

111 **Baseline characteristics, presentation, and diagnostics tests**

112 Between the 1st of June 2021 and the 1st of June 2023, 596 patients presented to the
113 hospital with AF as the primary diagnosis on admission, all of whom were of Arab
114 descent. Only 121 patients (20%) were known to have AF before presentation
115 without the ability to differentiate between paroxysmal and persistent AF due to the
116 lack of Holter monitoring and previous clinic follow-up. The most common presenting
117 complaint was palpitations in 335 patients (56%), followed by shortness of breath in
118 171 patients (29%), chest pain in 40 patients (7%), clinical heart failure in 28 patients
119 (5%) and syncope in 23 patients (4%). Around three-quarters of patients were
120 current smokers. Demographic and lab results are demonstrated in Table 1.
121 Moderate to severe valvular heart disease (VHD) was present in 90 patients (15%),

122 of which 20 (22%) had rheumatic mitral stenosis, 18 (20%) had moderate to severe
123 tricuspid regurgitation, 29 (21%) had moderate to severe mitral regurgitation, 30
124 (33%) had moderate to severe aortic stenosis, and three (3%) had surgically
125 corrected metallic aortic valve. This information was extracted from previous
126 echocardiograms that patients underwent. Only 3 out of 20 patients (15%) with
127 active thyroid disease were on medical treatment. When stratified by length Of stay,
128 patients admitted for \geq four days had higher rates of smoking, hypertension, VHD,
129 and faster heart rate (HR) on admission.

130

131 **Treatments**

132 Management strategies were stratified into rhythm control, rate control or combined
133 approach based on clinical judgement and available resources. A rhythm control
134 strategy was adopted in 230 patients (39%). This was done exclusively using
135 pharmacological therapy, with amiodarone being the only drug available. The regime
136 used for all patients was an intravenous (IV) loading dose of 300mg followed by an
137 oral maintenance dose of 200 mg twice a day (BD) for a week, then 200 mg once a
138 day (OD) after that. Bisoprolol was used with amiodarone for additional rate control
139 in 131 patients (57% of amiodarone patients). Direct current cardioversion (DCCV)
140 was used in an emergency setting for ten patients during admission due to
141 hemodynamic instability, with eight being successful after a single shock and two
142 passing away due to degeneration to asystole. Elective DCCV was not used in this
143 cohort, nor were any patients scheduled for one after discharge. None of the patients
144 was referred to catheter ablation or left atrial appendage closure, which is not offered
145 in the city. Monotherapy rate control was employed in 366 patients (61%). Metoprolol

146 was the only IV rate-control drug used in 90 patients (15%) with 5 mg to 15 mg
147 boluses. The two available oral drugs were bisoprolol 2.5-10 mg, used in 249
148 patients (42%), followed by verapamil 120mg BD to three times a day (TDS), used in
149 28 patients (5%). The HR was reduced significantly in all patients on discharge from
150 137 (120-152) BPM to 76 (65-90) BPM, $P<0.0001$.

151 Oral anticoagulation was used in 500 patients (84%) based on the CHA₂DS₂-
152 VASc score (cut-offs of ≥ 1 for males and ≥ 2 for females were used for
153 anticoagulation) or if a rhythm control strategy was adopted. Of these, Warfarin was
154 used in 21 patients (4%), of which 18 had rheumatic heart disease, and three had a
155 metallic heart valve. The rest of the patients (n=479) received a direct oral
156 anticoagulant (DOAC) based on availability. The available DOACs were apixaban
157 (2.5-5mg BD) and rivaroxaban (15-20mg OD). Urological and gastrointestinal bleeds
158 occurred in 12 patients within 36 hours of anticoagulation initiation, but none were
159 fatal. Eight patients resumed lower-dose DOAC after careful patient counselling and
160 shared decision-making, while the rest discontinued, accepting the risk of cardio-
161 embolic events.

162

163 **Inpatient outcomes and predictors**

164 Inpatient mortality was 5% (n=31) after a median hospital admission of 4 (3-7) days.
165 CV mortality occurred in 28 patients (4.7%), while three died from hospital-acquired
166 infections (0.3%). The remaining patients were discharged home after a median of 4
167 (2-5) days. Limited facilities and recourses did not allow patients to be scheduled for
168 an outpatient follow-up clinic or diagnostic tests such as a Holter monitor or a
169 transthoracic echocardiogram. Table 2 demonstrates univariable and multivariable

170 logistic regressions in relation to mortality. The univariable logistic regression model
171 concluded that valvular heart disease, COPD, smoking, IHD and thyroid disease with
172 a higher T4 were associated with increased inpatient mortality. In a multivariable
173 model consisting of age, gender, smoking status, thyroid disease, COPD and VHD, it
174 was found that the presence of smoking (aOR: 1.6, 95% CI: 1.3 to 2.1, P=0.04,
175 thyroid disease (aOR= 9.7, 95% CI= 1.2 to 91.6, P<0.001), COPD (aOR: 82, 95% CI:
176 12.7 to 711, P<0.001) and VHD (aOR= 9.1, 95% CI: 1.7 to 55.1, P<0.001) were
177 independent risk factors of CV inpatient mortality. Adding smoking, COPD, thyroid
178 disease, and VHD to the base model provided the best AUC to predict inpatient
179 mortality (AUC=0.9, Table 3 .

180

181 **Discussion**

182 This is the first study to address AF inpatient treatment patterns and clinical
183 outcomes in Syria, a country suffering from conflict since 2011 and recently hit by
184 devastating earthquakes (6). We report an AF inpatient cohort of 596 patients. The
185 main findings include that the hospitalised AF Syrian patients were relatively younger
186 than other neighbouring countries (7), the lack of elective rhythm control regardless
187 of patient's age, comorbidities or symptom burden due to the paucity of resources,
188 so there was blank rate control strategy adopted in most patients, and that current
189 smoking, thyroid disease, COPD and VHD were independent risk factors of CV
190 inpatient mortality in a prediction model that has an AUC of 0.9.

191 There has been a significant increase in AF prevalence in low-income countries in
192 the last 20 years (8). The Syrian population have been living in poverty and life
193 stress for the previous ten years, both of which are suggested to promote AF (4, 9).

194 This inpatient cohort is relatively younger than patients admitted in high-income
195 countries. For example, 453,060 hospitalised patients with AF in the US had a mean
196 age of 70.1, more than our cohort (10). Our cohort was even younger than the
197 Jordanian cohort, with a mean age of 68 (7). This is likely due to the lack of primary
198 or secondary care risk factor control owing to the lack of funding and resources. The
199 high smoking rate likely affected our cohort's AF incidence (11).

200 Moreover, clinicians did adopt the latest evidence and treatment guidelines to the
201 best of their abilities, but limited resources hindered this (12). Appropriate rate and
202 rhythm control strategies were conducted using available resources, and DCCV was
203 appropriately used in hemodynamically unstable patients. This contributed to the
204 relatively acceptable inpatient outcomes, knowing the challenging circumstances in
205 Syria. There is ongoing evidence worldwide about the benefit of early rhythm control
206 on symptoms, stroke risk, quality of life and cardiovascular outcomes, which can
207 benefit this cohort (13-15). However, this approach could not be implemented due to
208 the intensive follow-up, resources and the availability of antiarrhythmic drugs and
209 ablation centres, which are unavailable in Syria. (16). This should be an area for
210 improvement to optimise long-term outcomes and avoid re-admissions. Therefore,
211 follow-up data is suggested in future studies.

212 Our model was highly predictive of inpatient CV mortality. Current smoking (17) and
213 COPD (18) were associated with increased mortality in previous studies but not in a
214 predominantly Arab cohort. This study could be used to validate these findings in
215 such ethnicity. A history of thyroid disease is known to increase AF risk but has not
216 been shown to increase mortality (19). Almost 15% of our cohort with thyroid disease
217 were on active treatment, which could have contributed to current results. To
218 optimise AF treatment, active steps should be taken to educate patients about

219 modifiable risk factors and lifestyle triggers. VHD is known to cause AF (20), and a
220 community-based study suggested that moderate to severe biological VHD
221 increased mortality (21). This can be reflected in our cohort, especially with the
222 difficulty of accessing a cardiac surgery service due to poor/damaged infrastructure.
223 Many of these patients remain untreated, which contributes to increased mortality.
224 This highly predictive model can be used from a patient's perspective to address
225 smoking (which will improve COPD management) and encourage compliance with
226 thyroid medications.

227 Furthermore, the predictive model could be essential for policymakers to ensure
228 these patients have follow-up to address risk factors, especially a potential need for
229 surgical treatment for VHD. From a physician's perspective, this model helps identify
230 patients at a high risk of deterioration to ensure early escalation and prompt
231 treatment. In case of limited follow-up availability, these patients could be prioritised
232 to prevent CV mortality. More resources are required to ensure guidelines adherence
233 and follow-up of the most vulnerable patients to achieve better outcomes.

234

235 **Conclusion**

236 Syrian inpatients admitted acutely with AF are relatively young, and the limited
237 resources prevented optimal AF management, especially elective rhythm control,
238 despite physicians' best efforts. Current smoking, thyroid disease, COPD and VHD
239 were independent risk factors for CV inpatient mortality.

240

241 **Limitations**

242 Our study had limitations. Our data collection was limited to a single tertiary care
243 centre in Latakia. This city was less affected by the Syrian war than other northern
244 and eastern regions of Syria. Therefore, our results might not generalise to other
245 centres/regions, knowing the extreme heterogeneity in the quality and quantity of
246 hospital supplies and staff. Additionally, our analysis included only routinely
247 collected data within the medical records and by the number of patients who
248 presented to the hospital. Therefore, we missed the other variables that may have
249 impacted mortality. Nevertheless, our study successfully provided significant, timely
250 findings that may prove helpful in improving the care provided and reducing mortality
251 in patients with AF.

252

253 **Data availability**

254 Data relating to this study are available upon reasonable request from the
255 corresponding author.

256

257 **Funding sources**

258 There is no funding to declare for this study.

259

260 **Conflicts of interest**

261 No conflicts of interest to report.

262

263 **Acknowledgements**

264 AK is supported by a clinical research fellowship from Abbott. GA Ng is supported by
265 a British Heart Foundation Programme Grant (RG/17/3/32,774) and the Medical
266 Research Council Biomedical Catalyst Developmental Pathway Funding Scheme
267 (MR/S037306/1). JB is supported by the NIHR Academic Clinical Fellowship.

268

269 **Ethical statement**

270 This study was reviewed and approved by the institutional ethical committee of the
271 Tishreen University Hospital.

272

273 **Authors contributions**

274 IA designed the study, analysed the data and wrote the first manuscript draft. AA,
275 AA, AT and YM managed data collection. AK, IH, SS, AM, GAN, RS, and JB
276 reviewed and edited the manuscript.

277

278 **References**

- 279 1. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. *Nature Reviews*
280 *Cardiology*. 2014;11(11):639.
- 281 2. Al-Shamkhani W, Ayetey H, Lip GY. Atrial fibrillation in the Middle East: unmapped,
282 underdiagnosed, undertreated. *Expert review of cardiovascular therapy*. 2018;16(5):341-8.
- 283 3. Akiki D, El Hage S, Wakim E, Safi S, Assouad E, Salameh P. Atrial Fibrillation in the Arab
284 World: A Bibliometric Analysis of Research Activity from 2004 to 2019. *Journal of Cardiac*
285 *Arrhythmias*. 2021;34(1):12-22.
- 286 4. Essien UR, McCabe ME, Kershaw KN, Youmans QR, Fine MJ, Yancy CW, et al. Association
287 Between Neighborhood-Level Poverty and Incident Atrial Fibrillation: a Retrospective Cohort Study. *J*
288 *Gen Intern Med*. 2022;37(6):1436-43.
- 289 5. Vandembroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al.
290 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and
291 elaboration. *PLoS medicine*. 2007;4(10):e297.
- 292 6. Naddaf M. Turkey-Syria earthquake: What scientists know. *Nature*. 2023.

- 293 7. Hammoudeh A, Khader Y, Tabbalat R, Badaineh Y, Kadri N, Shower H, et al. One-Year Clinical
294 Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib)
295 Study. *International Journal of Vascular Medicine*. 2022;2022:4240999.
- 296 8. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing
297 epidemic and public health challenge. *International Journal of Stroke*. 2020:1747493019897870.
- 298 9. Patel D, Mc Conkey ND, Sohaney R, Mc Neil A, Jedrzejczyk A, Armaganijan L. A systematic
299 review of depression and anxiety in patients with atrial fibrillation: the mind-heart link.
300 *Cardiovascular Psychiatry and Neurology*. 2013;2013.
- 301 10. Jackson SL, Tong X, Yin X, George MG, Ritchey MD. Emergency Department, Hospital
302 Inpatient, and Mortality Burden of Atrial Fibrillation in the United States, 2006 to 2014. *The*
303 *American Journal of Cardiology*. 2017;120(11):1966-73.
- 304 11. Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of atrial fibrillation: a
305 systematic review and meta-analysis of prospective studies. *European journal of preventive*
306 *cardiology*. 2018;25(13):1437-51.
- 307 12. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC
308 Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with
309 the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and
310 management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the
311 special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *European Heart*
312 *Journal*. 2020;42(5):373-498.
- 313 13. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control
314 Therapy in Patients with Atrial Fibrillation. *New England Journal of Medicine*. 2020;383(14):1305-16.
- 315 14. Guertin JR, Dorais M, Khairy P, Sauriol L, Matteau A, Poulin F, et al. Atrial fibrillation: a real-
316 life observational study in the Québec population. *Can J Cardiol*. 2011;27(6):794-9.
- 317 15. Kim D, Yang P-S, You SC, Sung J-H, Jang E, Yu HT, et al. Treatment timing and the effects of
318 rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. *bmj*. 2021;373.
- 319 16. Fouad FM, Sparrow A, Tarakji A, Alameddine M, El-Jardali F, Coutts AP, et al. Health workers
320 and the weaponisation of health care in Syria: a preliminary inquiry for The Lancet–American
321 University of Beirut Commission on Syria. *The Lancet*. 2017;390(10111):2516-26.
- 322 17. Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjøth F, Overvad K, et al. The Impact of
323 Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. *Chest*.
324 2014;145(3):559-66.
- 325 18. Ye J, Yao P, Shi X, Yu X. A systematic literature review and meta-analysis on the impact of
326 COPD on atrial fibrillation patient outcome. *Heart & Lung*. 2022;51:67-74.
- 327 19. Bruere H, Fauchier L, Brunet AB, Pierre B, Simeon E, Babuty D, et al. History of thyroid
328 disorders in relation to clinical outcomes in atrial fibrillation. *The American Journal of Medicine*.
329 2015;128(1):30-7.
- 330 20. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk
331 factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *Jama*.
332 1994;271(11):840-4.
- 333 21. Thomas KL, Jackson LR, Shrader P, Ansell J, Fonarow GC, Gersh B, et al. Prevalence,
334 characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights
335 from the ORBIT-AF (outcomes registry for better informed treatment for atrial fibrillation). *Journal of*
336 *the American Heart Association*. 2017;6(12):e006475.